
SAGE Therapeutics (SAGE) P/E Ratio
P/E Ratio as of Jun 30, 2025: -1.57
Average-1.37
Median-1.39
Minimum-1.60
Maximum-1.13
-1.57
Past Month-0.46 (41.44%)
The P/E ratio for SAGE Therapeutics (SAGE) is -1.57 as of Jun 30, 2025. This represents a increase of 34.19% compared to its 12-month average P/E ratio of -1.17. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
SAGE Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
SAGE Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing SAGE Therapeutics to industry peers.
SAGE Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
SAGE Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing SAGE Therapeutics to industry peers.
SAGE Therapeutics (SAGE) P/E Ratio Insights
See SAGE Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in SAGE Therapeutics (SAGE)
Order type
Buy in
Order amount
Est. shares
0 shares
SAGE Therapeutics (SAGE) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jun 2, 2025 | $6.62 | -1.14 |
May 1, 2025 | $7.48 | -1.29 |
Apr 1, 2025 | $7.86 | -1.19 |
Mar 3, 2025 | $7.20 | -1.09 |
Feb 3, 2025 | $7.26 | -1.30 |
Jan 2, 2025 | $5.78 | -1.04 |
SAGE Therapeutics (SAGE) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -1.57 | +61.86% |
2024 | -0.97 | -50.76% |
2023 | -1.97 | -55.43% |
2022 | -4.42 | -18.90% |
2021 | -5.45 | -169.87% |
2020 | 7.80 | — |
FAQs About SAGE Therapeutics (SAGE) P/E ratio
The latest P/E ratio of SAGE Therapeutics (SAGE) is -1.57, as of Jun 30, 2025. This is calculated based on its current stock price and earnings per share (EPS).
SAGE Therapeutics’s last 12-month average P/E ratio is -1.17, compared to its current P/E ratio of -1.57. This reflects a increase of 34.19%.
SAGE Therapeutics’s current P/E ratio of -1.57 is higher than its last 12-month average P/E of -1.17. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
SAGE Therapeutics’s average P/E ratio over the last 3 years is -2.71. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
SAGE Therapeutics’s average P/E ratio over the last 5 years is -1.56. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.